EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients-Reference-Cited by-同舟云学术

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

Published:2008-04 Issue:4 Volume:19 Page:717-723
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cappuzzo F.,Finocchiaro G.,Rossi E.,Jänne P.A.,Carnaghi C.,Calandri C.,Bencardino K.,Ligorio C.,Ciardiello F.,Pressiani T.,Destro A.,Roncalli M.,Crino L.,Franklin W.A.,Santoro A.,Varella-Garcia M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/4/717/578775/mdm492.pdf

Reference36 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer);Thatcher;Lancet,2005

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer;Kindler;Am J Clin Oncol,2005

5. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

Cited by 233 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring of selected anticancer drugs;Therapeutic Drug Monitoring;2024

2. Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease;Egyptian Pharmaceutical Journal;2023-10

3. Metastatic Lung Tumors from Colorectal Cancer with <i>EGFR</i> Mutations That Responded to Osimertinib;Internal Medicine;2023-03-01

4. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

5. Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy;Science Advances;2022-03-18